Earnings Call · Q2 FY2022·2022-08-03

Q2 22EPS +2.63%·Rev n/aQ1 22EPS -4.11%·Rev n/aQ4 21EPS +15.66%·Rev n/aQ3 21EPS +26.89%·Rev n/a⚠ consensus missing

Jazz Pharmaceuticals plc JAZZ

Andrea Flynn — Investor Relations or Communications

Bruce Cozadd — President and Chief Executive Officer

Dan Swisher — Executive, likely Chief Commercial Officer or similar

Rob Iannone — Executive, likely Head of R&D or similar

Renée Galá — Executive, likely Chief Financial Officer

−0.3%1d on move date−0.3% vs SPY3d+1.6%5d+3.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more JAZZ calls or request research access.

More JAZZ calls Browse calls Request research access